Head and Neck Cancer Therapeutics Market Analysis

Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy)

Immunotherapy segment is projected to dominate head and neck cancer therapeutics market share of around 51.8% by the end of 2037. The segment growth can be attributed to the growing development of new therapeutics. For instance, in July 2024, a clinical-stage biotechnology company, Immutep Limited, announced positive outcomes from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial, which assessed eftilagimod alfa in conjunction with MSD's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), as the first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma who exhibit negative PD-L1 expression. For patients with advanced or recurrent head and neck malignancies, immunotherapy is seen to be a viable treatment option. By using the body's immune system to identify and combat cancer cells, this method provides an alternative to conventional treatments like radiation, chemotherapy, and surgery.

Route of Administration (Injectable, Oral)

In head and neck cancer therapeutics market, injectable segment is expected to capture revenue share of over 57.6% by 2037. The segment growth can be attributed to the increased development of advanced injectable therapies as they provide novel and effective treatment options. IV injectables are used to provide several popular immunotherapy medications for head and neck cancer, including pembrolizumab (Keytruda) and nivolumab (Opdivo).

Furthermore, precise control over dosage and administration is made possible by injectables, which is crucial for maximizing effectiveness and limiting side effects in cancer treatment. Because of the proximity of critical structures including the airway and nerves, precision is important in head and neck tumors, where cautious management is necessary. This increases the adoption rate of injectables.

Our in-depth analysis of the global head and neck cancer therapeutics market includes the following segments: